Health

Results: 6793-6804 of 8690

PR Newswire associated0

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

PR Newswire associated0

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

Notice of Annual General Meeting (AGM) of Bioretec Ltd

PR Newswire associated0

The Adelaïde Group announces 18% turnover growth for 2023

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

New Hope in Battle Against C. diff: New Surface "Active" Technology with Residual Efficacy Kills Spores in 30 Seconds